"Most HIV-positive women and children exposed to nevirapine (Viramune) during the peripartum period can go on to use the drug when they need highly active antiretroviral therapy (HAART) for their own health, researchers reported. But a significant minority will not respond to nevirapine-based treatment, even if they do not have resistance to the drug, according to two reports [here and here] in the Oct. 14 issue of the New England Journal of Medicine," MedPage Today reports (10/13). The authors of the second study write that both trials "strongly support the use of ritonavir-boosted lopinavir for the treatment of women and children who have had prior exposure to single-dose nevirapine" HealthDay News/ModernMedicine writes (10/13). The studies "helped influence the World Health Organization (WHO) to change its guidelines this year for the treatment of HIV infection in certain women and children," according to an NIH press release (10/13).
Back to other news for October 2010
This information was reprinted from kff.org with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives, and sign up for email delivery. © Henry J. Kaiser Family Foundation. All rights reserved.